Biocon Becomes Latest Stelara Challenger In US
Indian Biosimilars Giant Receives FDA Approval For Yesintek Version Of Ustekinumab
Biocon has become the latest ustekinumab biosimilar developer to garner approval from the US Food and Drug Administration – and the Indian giant already has a settlement in place that will allow it to be among the first to launch in 2025.
